Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,418 active trials60 approved drugs271 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,888 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,375)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04094142 | Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 66 | Seoul National University HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03994913 | Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma | completed | Phase 1 / Phase 2 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 14, 2023 |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT01182415 | High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT01256398 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03238599 | Pedometer Activity Monitoring After ASCT(PAMAL) | completed | Phase 2 | 62 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT02546440 | Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)(DMF-CTCL) | completed | Phase 2 | 25 | Universitätsmedizin MannheimOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT03492775 | First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years(GABe2016) | completed | Phase 2 | 46 | Prof. Dr. Wolfgang HiddemannOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT00783367 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | completed | Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01238692 | A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | completed | Phase 2 | 42 | Sarit AssoulineOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00199030 | Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath | completed | Phase 2 | 8 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT02840539 | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma(BATMAN) | completed | Phase 2 | 19 | Seoul National University HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 85 | Genentech, Inc.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT02419287 | Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | completed | Phase 2 | 12 | University of Milano BicoccaOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT05338047 | Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant | completed | Phase 2 | 30 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02853370 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | completed | Phase 2 | 78 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 2 | Feb 1, 2023 | clinicaltrials |
| NCT00005780 | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02342665 | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | completed | Phase 1 / Phase 2 | 25 | BayerINDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | completed | Phase 2 | 136 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02440464 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | completed | Phase 2 | 57 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT00912223 | Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) | completed | Phase 2 | 65 | Medical College of WisconsinOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT02963493 | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(HORIZON) | completed | Phase 2 | 157 | Oncopeptides ABINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 93 | Seagen Inc.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03200015 | Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02654132 | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | completed | Phase 2 | 117 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT02722941 | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Apr 18, 2023source: clinicaltrials